France-based Selexis has expanded its collaboration with Agenus, a clinical-stage immuno-oncology company, by signing additional commercial license agreements, it was reported yesterday.
According to the new commercial license agreements, Agenus will leverage Selexis' modular SUREtechnology Platform for the rapid, stable, and cost-effective production of its therapeutic proteins.
The Selexis SUREtechnology Platform is claimed to improve the way mammalian cells are utilised in the discovery, development and manufacturing of recombinant proteins and drugs. It offers key significant advantages over traditional approaches, allowing speed, high-yield, stability and flexibility.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886